Signaturefd LLC Acquires 212 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Signaturefd LLC raised its holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX) by 77.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 487 shares of the company’s stock after purchasing an additional 212 shares during the period. Signaturefd LLC’s holdings in Karuna Therapeutics were worth $154,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Lindbrook Capital LLC boosted its holdings in Karuna Therapeutics by 105.2% in the 4th quarter. Lindbrook Capital LLC now owns 238 shares of the company’s stock valued at $75,000 after purchasing an additional 122 shares during the period. abrdn plc bought a new stake in Karuna Therapeutics in the 4th quarter valued at about $10,197,000. Knights of Columbus Asset Advisors LLC boosted its holdings in Karuna Therapeutics by 94.5% in the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 2,241 shares of the company’s stock valued at $709,000 after purchasing an additional 1,089 shares during the period. AIA Group Ltd bought a new stake in Karuna Therapeutics in the 4th quarter valued at about $1,149,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Karuna Therapeutics by 10.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,770 shares of the company’s stock valued at $1,826,000 after purchasing an additional 550 shares during the period.

Karuna Therapeutics Price Performance

KRTX stock opened at $329.83 on Monday. The company has a 50 day simple moving average of $325.66 and a 200 day simple moving average of $272.73. The stock has a market cap of $12.58 billion, a price-to-earnings ratio of -28.14 and a beta of 1.18. Karuna Therapeutics, Inc. has a 1 year low of $158.38 and a 1 year high of $329.99.

Karuna Therapeutics (NASDAQ:KRTX) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($3.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.65) by ($0.36). Karuna Therapeutics’s quarterly revenue was down 100.0% on a year-over-year basis. During the same period last year, the business posted ($2.22) EPS. On average, equities research analysts anticipate that Karuna Therapeutics, Inc. will post -11.96 EPS for the current fiscal year.

Insider Buying and Selling at Karuna Therapeutics

In other Karuna Therapeutics news, insider Stephen K. Brannan sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $316.13, for a total value of $1,580,650.00. Following the completion of the transaction, the insider now directly owns 41,150 shares in the company, valued at approximately $13,008,749.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 13.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on KRTX shares. Mizuho reissued a “neutral” rating and issued a $330.00 price objective (up previously from $245.00) on shares of Karuna Therapeutics in a report on Friday, January 26th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $330.00 price target on shares of Karuna Therapeutics in a report on Tuesday, February 20th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $330.00 price target on shares of Karuna Therapeutics in a report on Thursday, March 14th. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Karuna Therapeutics currently has an average rating of “Hold” and a consensus price target of $293.92.

Karuna Therapeutics Company Profile

Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease.